Metastatic lung-cell cancer treatment with Erlotinib: its cutaneous side effects and practical management advice

Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.

Kiyohara Y, Yamazaki N, Kishi A.

J Am Acad Dermatol. 2013 Sep;69(3):463-72. doi: 10.1016/j.jaad.2013.02.025.

• Targeted treatments against cancers have enhanced therapeutic properties as compared with older treatments. But with this also comes an array of new unwanted side-effects which are the results of these specific targets.
• Erlotinib (metastatic non-small cell lung cancer) is no exception and with the side-effects also comes a mangement plan:

1. Acneiform rash
2. Xeroderma
3. Pruritus
4. Paronychia

• The authors also cover other side-effects, preventive measures as well as indications when erlotinib should be stopped.

For full access to the free article in the Journal of American Academy of Dermatology (JAAD), click here.

JAAD: click here to view abstracts from the current edition, articles in press, most cited articles and top 25 articles.

Contributors

Dr Christophe Hsu – dermatologist. Geneva, Switzerland